The silver lining in this article is the general education about diabetes and the benefit of ultra-rapid acting insulins.

It can't hurt to have this information being disseminated by any means at this stage of the game. If someone buys into the concept of ultra-rapid acting insulin and its close proximity to the natural physiology of the pancreas and then takes a deeper dive into the market, they'll quickly find that MNKD is a leader and likely will be for some time.

The harder they try to point out where Biodel will be successful, the greater the chances they'll choose to invest in MNKD instead. jmho